logo-loader
viewEden Research PLC

Eden Research narrows half-year losses, eyes larger sales footprint for Cedroz pesticide

Authorisation for Cedroz in the southern EU and emergency approval for its use in Italy meant its sales potential was expected to "singificantly" increase

Eden Research plc - Eden Research narrows half-year losses, eyes larger sales footprint for Cedroz pesticide

Eden Research plc (LON:EDEN) cut losses in the first half of its financial year as it eyed a larger sales footprint for its Cedroz pesticide.

The AIM-listed firm, which develops biopesticides to protect crops, animals and humans, reported that for the six months ended 30 June pre-tax losses had narrowed to £645,000 from £940,000 in the same period last year despite revenues contracting to £581,000 from £682,000.

READ: Eden Research set to enter period of “strong product sales growth”, says Cenkos

The lower losses appear to have resulted from reduced sales costs, which fell to £250,000 in the period from £479,000 a year ago.

Eden also reported that product sales in the first half had dropped to £450,000 from £680,000, although clarified that this was due to a change of production schedule and that the seasonality of its business meant most sales would be weighted to the second half.

Overall, current trading was in line with expectations, while the sales footprint for Cedroz was expected to increase “significantly” following final authorisation in the southern crop zones of the EU and emergency approval for its use in Italy.

As a result, Eden said its growth prospects were “steadily improving” and it had several product developments underway internally and with partner firms which should see it become a “global player” in the medium term.

In mid-morning trading on Wednesday, Eden’s shares were 3.1% lower at 9.6p.

Quick facts: Eden Research PLC

Price: 6.875 GBX

AIM:EDEN
Market: AIM
Market Cap: £26.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Eden Research PLC named herein, including the promotion by the Company of Eden Research PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn’s Leronlimab receives positive DSMC recommendation in ongoing Phase...

CytoDyn (OTCQB: CYDY) CEO Nader Pourhassan and Chief Scientific Advisor Dr Jay Lalezari joined Steve Darling from Proactive with news the company has had results from an independent Data Safety Monitoring Committee who completed its first safety review of the ongoing Phase 3 clinical trial of...

11 hours, 22 minutes ago

2 min read